KPL2 Inhibitors
Inhibitors of KPL2 play a crucial role in dampening the kinase's signaling and functional activity through a series of intricate molecular interactions within the cell. Certain inhibitors exert their effects by directly targeting the active site of KPL2, competitively obstructing the ATP binding necessary for its kinase activity, thereby preventing the phosphorylation of downstream targets. This direct inhibition is a key mechanism by which the cellular signaling that depends on KPL2's kinase function is attenuated. In contrast, other compounds indirectly inhibit KPL2 by modulating upstream signaling pathways. These inhibitors target various receptors, kinases, and enzymes that lie upstream of KPL2, disrupting the cascade of events required for its activation. By doing so, these molecules effectively reduce KPL2's ability to participate in and propagate cellular signals that lead to growth, proliferation, or other KPL2-dependent processes.
Additionally, some inhibitors interact with key signaling molecules such as mTOR, Akt, PI3K, and members of the MAPK family, which are sometimes involved in regulating KPL2 activity. By disrupting the function of these molecules, the inhibitors can lead to a decrease in KPL2 signaling. Inhibition of PI3K, for example, results in downstream effects that include a reduction in KPL2 activity due to the tight regulatory relationship between PI3K signaling and KPL2's role. Similarly, by impeding the MAPK/ERK pathway or the JNK pathway, some inhibitors indirectly suppress the activity of KPL2.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A selective inhibitor of PI3K, LY 294002 prevents the phosphorylation and activation of AKT. Given that KPL2 functions downstream of AKT, inhibition of PI3K activity results in reduced phosphorylation of KPL2, thereby suppressing its kinase activity and signaling function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As an inhibitor of MEK, which is upstream in the MAPK/ERK pathway, PD 98059 prevents the activation of ERK. KPL2, being part of the MAPK/ERK pathway, depends on the sequential phosphorylation from MEK to ERK for its full activity, thus PD 98059 indirectly dampens KPL2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin forms a complex with FKBP12 and binds to mTOR, inhibiting its activity. This leads to a decrease in p70 S6 kinase phosphorylation and activity, which is required for KPL2 activation. Consequently, rapamycin causes an indirect reduction in KPL2 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
By inhibiting p38 MAPK, SB 203580 disrupts downstream signaling that may include KPL2. As p38 MAPK influences various substrates and processes, the inhibition of its activity can lead to a decrease in KPL2-mediated signaling events. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP 2 is a Src family kinase inhibitor. Since Src kinases can phosphorylate and activate multiple downstream proteins including KPL2, PP 2 indirectly decreases KPL2 activation and its subsequent signaling cascades by blocking Src kinase activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 prevents the phosphorylation of c-Jun and the activation of the transcription factor AP-1. As KPL2 is regulated by AP-1-dependent transcription, inhibition by SP600125 leads to reduced KPL2 expression and activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By curtailing PI3K activity, wortmannin diminishes AKT phosphorylation. This, in turn, leads to a decrease in downstream KPL2 activity, as KPL2 is activated by pathways involving PI3K/AKT signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
This compound inhibits MEK1/2, thereby preventing the activation of ERK1/2 in the MAPK pathway. As KPL2 activity is regulated by ERK-dependent signaling, U0126 indirectly leads to decreased KPL2 activity by inhibiting upstream kinase activation. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
As an ERK1/2 inhibitor, LY3214996 specifically targets the MAPK/ERK pathway, preventing the activation of these kinases. The inhibition of ERK1/2 leads to a concomitant reduction in KPL2 activity, which is modulated by the MAPK/ERK pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, which includes Src family kinases. As Src kinases can activate KPL2, the use of Dasatinib would result in decreased activation of KPL2 due to less phosphorylation by Src kinases. | ||||||